Skip to main content
Capstone

Gargine: Does a long acting recombinant DNA insulin used as a backland for basal insulin improve HbA1c values compared to the use of other long acting and intermediate acting insulin?

1 August 2002

Abstract

Objective To look at the effect of Glargine on HbA1c values compared to previous insulin regimen of other intermediate and long acting insulins and their effect on HbA1c values in type 1 diabetic patients and to determine if Glargine improves these values.

Design and Methods A retrospective chart review from six months to one year prior to starting Glargine and six months to one year after using Glargine in type 1 diabetics. A total of 49 patients met this criteria.

Setting All 49 patients were from The Vancouver Clinic in Vancouver, WA.

Results There was a slight reduction in HbA1c values and BMI values. The HbA1c values on the previous insulin regimen was 8.15 +/- 1.59% and on Glargine HbA1c values were 8.09 +/- 1.72% with a total mean difference between the two values of 0.0592. The BMI value on previous insulin regimen was 26 +/- 4.40(kg/m2 ) and on Glargine 25.7 +/- 4.31(kg/m2 ).

Conclusion There was a positive result in both HbA1c and BMI values. These small reductions may help improve glycemic control, which in return will help limit microvascular complications due to diabetes without hypoglycemic effects.


Files

Files are restricted to Pacific University. Sign in to view.